Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGOBSERVATIONAL

MItral Regurgitation Risk Assessment and CLinical modElling

MItral Regurgitation Risk Assessment and CLinical modElling (MIRACLE Study)

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Mitral regurgitation (MR) is a common valvular heart disease worldwide, and untreated severe MR is associated with an elevated risk of heart failure and mortality. According to causes, MR could be divided into primary or secondary MR. The risk factors of mortality or heart failure hospitalization in different types of MR patients are under intensive investigation. MItral Regurgitation risk Assessment and CLinical modElling (MIRACLE) study is a prospective cohort study including adult patients diagnosed with ≥ moderate MR during hospitalization. Comprehensive echocardiographic examination was conducted at baseline evaluating valvular heart disease severity, atrial and ventricular systolic/diastolic function, pulmonary artery systolic pressure (PASP), etc. We aim to evaluate the prognostic risk factors of patients with MR and construct a prognostic clinical model to guide clinical decision-making.

Who May Be Eligible (Plain English)

Who May Qualify: - Patients diagnosed with ≥ moderate mitral regurgitation during hospitalization. - Aged over 18 yrs. Who Should NOT Join This Trial: - Patients unable to provide written consent. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Patients diagnosed with ≥ moderate mitral regurgitation during hospitalization. * Aged over 18 yrs. Exclusion Criteria: * Patients unable to provide written consent.

Locations (1)

The First Affiliated Hospital of Sun Yat-sen Univerity
Guangzhou, Guangdong, China